Our news

CFZ533 starts in UZ Leuven

09. February 2021

Yesterday February 8th, the first patient at UZ Leuven was treated with Iscalimab. Safety and efficacy of CFZ533 on preservation of pancreatic β-cell function, will be evaluated in new onset type one diabetes, age 15-21. This trial is a collaboration between Novartis & INNODIA.